Eye­ing clin­i­cal proof-of-con­cept for HER3 drug, Am­gen-part­nered biotech scores $125M for pre­ci­sion an­ti­bod­ies

When it comes to re­draw­ing the bound­aries of what pro­teins are drug­gable, small mol­e­cules have soaked up the spot­light. Hordes of new en­trants — in­hibitors, al­losteric …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER